TerThera B.V. has achieved a major new milestone by producing over 25,000 GBq (675 Ci) of Terbium-161. Thanks to this record-breaking production, the crucial precursor is now available in abundance on a full global scale, supplying clinical trials and multiple R&D pipelines across six continents. Since its launch in 2022, TerThera has been fully dedicated to making this isotope widely available, a mission that is now accelerated by a rapidly increasing demand from hospitals, biotech companies, and Big Pharma alike.
